143.68

0.47% -0.68

After Hours: 143.68

Krystal Biotech Inc (KRYS)

Overview News Price History Option Chain Financials Why KRYS Down? Discussions Forecast

Krystal Biotech Inc stock is traded at $143.68, with a volume of 350.78K. It is down -0.47% in the last 24 hours and up +0.04% over the past month. Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Previous Close:

$144.36

Open:

$144.17

24h Volume:

350.78K

Relative Volume:

0.99

Market Cap:

$4.16B

Revenue:

$290.51M

Net Income/Loss:

$89.16M

P/E Ratio:

48.05

EPS:

2.99

Net Cash Flow:

$119.18M

1W Performance:

-4.39%

1M Performance:

+0.04%

6M Performance:

-19.46%

1Y Performance:

-26.56%

1-Day Range:

$141.25

$145.42

1-Week Range:

$136.73

$151.45

52-Week Range:

$122.80

$207.84

Krystal Biotech Inc Stock (KRYS) Company Profile

Name

Krystal Biotech Inc

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

(412) 586-5830

Address

2100 WHARTON STREET, PITTSBURGH, PA

Employee

275

Twitter

@KrystalBiotech

Next Earnings Date

2024-11-04

Latest SEC Filings

KRYS's Discussions on Twitter

Compare KRYS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KRYS Krystal Biotech Inc	143.68	3.98B	290.51M	89.16M	119.18M	2.99
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-25	Initiated	Jefferies	Buy
Aug-06-24	Downgrade	Citigroup	Buy → Neutral
Nov-20-23	Initiated	Goldman	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-12-23	Initiated	Citigroup	Buy
Sep-07-23	Initiated	Berenberg	Buy
Apr-18-23	Initiated	Stifel	Buy
Feb-28-23	Upgrade	Goldman	Neutral → Buy
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-18-22	Initiated	BofA Securities	Buy
Jul-20-21	Upgrade	Goldman	Neutral → Buy
Sep-18-20	Initiated	B. Riley FBR	Buy
Jun-04-20	Initiated	Evercore ISI	Outperform
Sep-24-19	Initiated	Goldman	Neutral
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jun-24-19	Reiterated	Chardan Capital Markets	Buy
Jun-24-19	Reiterated	H.C. Wainwright	Buy
May-30-19	Initiated	Guggenheim	Buy
Sep-11-18	Initiated	Cantor Fitzgerald	Overweight

View All

Krystal Biotech Inc Stock (KRYS) Latest News

Sep 12, 2025

Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Sep 12, 2025

TSCM U.S. Small Cap Growth Strategy Reduced Its Position in Krystal Biotech (KRYS) - Yahoo Finance

Sep 12, 2025

Sep 11, 2025

EP Wealth Advisors LLC Makes New Investment in Krystal Biotech, Inc. $KRYS - MarketBeat

Sep 11, 2025